Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyBlue Cross Blue Shield Oklahoma Testosterone Cover…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB009

    Testosterone

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB009 alerts

    Get alerted when Policy CPCPLAB009 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Laboratory coverage and reimbursement criteria for serum testosterone and related hormone tests for Blue Cross Blue Shield - Oklahoma members; governs when tests are reimbursable and when they are not, and provides testing/assay guidance for providers.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyTestosterone
    Policy CodePolicy CPCPLAB009
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewJan 12, 2026
    Next Review Date
    Key ActionOrder serum total testosterone as the initial test for suspected cases and document clinical indication and timing to support reimbursement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10numbered reimbursement items listed
    1.0policy version

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    May 1, 2026
    plan effective date
    CDC HoStassay certification recommended
    Not reimbursablesaliva testing

    Coverage Criteria for Testosterone and Related Tests

    Covered indications and related testing

    Measurement of serum total testosterone may be reimbursable when ANY of the following situations apply:

    Covered indications for serum total testosterone: a. Symptoms of androgen deficiency or androgen excess in males — initial screening requires two measurements at least 24 hours apart; if initial screening is normal but symptoms persist, follow-up testing allowed no sooner than 60 days after initial screening. b. Monitoring treatment response in men taking enzyme inhibitors for prostate cancer. c. Men receiving testosterone replacement therapy (every 2-3 months for the first year after initiation of therapy or after a change in therapeutic dosage; annually thereafter). d. Gender-dysphoric/gender-incongruent persons: baseline, during treatment and for therapy monitoring. e. Symptomatic females being evaluated for conditions associated with androgen excess (e.g., polycystic ovary syndrome and functional hypothalamic amenorrhea).

    From reimbursement items 1a-1e

    Additional reimbursable tests when indicated: 2. For males with total testosterone confirmed as low or borderline low and who have hypogonadism, gynecomastia, and/or other forms of testicular hypofunction: annual measurements of serum free testosterone, SHBG, and/or albumin may be reimbursable. 3. For individuals suspected of having a disorder accompanied by increased or decreased SHBG levels: measurement of serum free testosterone using a medically accepted algorithm based on total serum testosterone, SHBG, and/or albumin or measurement of bioavailable testosterone may be reimbursable. 4. Prior to initiating testosterone therapy for males with gynecomastia: once per lifetime serum estradiol measurement may be reimbursable. 5. For individuals with ambiguous genitalia, hypospadias, or microphallus: measurement of serum dihydrotestosterone for diagnosis of 5‑alpha reductase deficiency may be reimbursable.

    From reimbursement items 2-5

    Measurement of serum free testosterone and/or bioavailable testosterone as a primary test (that is, performed without a prior serum total testosterone measurement) is not reimbursable.

    Testing for serum total, free, or bioavailable testosterone in asymptomatic individuals or for non‑specific symptoms is not reimbursable and is considered not medically necessary.

    Measurement of serum testosterone for the purpose of identifying androgen deficiency in women is not reimbursable.

    The use of saliva specimens for measurement of testosterone is not reimbursable and claims for saliva testing will be denied.

    Measurement of serum dihydrotestosterone is not reimbursable for indications other than those specifically listed as reimbursable in the policy.

    Tests ordered for asymptomatic individuals or for non‑specific symptoms are considered not medically necessary and will not be reimbursed.

    Specific Clinical Indications Considered Reimbursable

    Symptoms of androgen deficiency/excess in males — initial screening rules

    Covered when ALL of the following are met:

    Initial male screening: Two separate serum total testosterone measurements obtained at least 24 hours apart.Two measurements

    Initial screening requirement

    Follow-up if initial normal but symptoms persist: Follow-up serum total testosterone testing is allowed no sooner than 60 days after the initial screening.No sooner than 60 days

    Timing for repeat testing when symptoms persist

    Exclusions for primary testing: Measurement of serum free and/or bioavailable testosterone as a primary test without a prior serum total testosterone measurement is not reimbursable.

    Testing Frequency and Timing Rules

    inv-22: serum total testosterone — Two (frequency descriptor)
    FrequencyTwo serum total testosterone measurements (initial screening) at least 24 hours apart
    When to collectSamples should be collected in the early morning, after fasting (see Note 1)
    PurposeInitial screening for symptoms of androgen deficiency or androgen excess in males
    inv-23: follow-up total testosterone when initial normal but symptoms persist — No sooner than 60 days
    Minimum interval for follow-upNo sooner than 60 days after initial screening when initial total testosterone was normal but symptoms persist
    Applies toMales with persistent symptoms of androgen deficiency or excess after a normal initial screen

    Procedure Codes and Coding Guidance

    Procedure Codes referencedmixed
    No codes listed

    Provider Actions, Documentation, and Billing Requirements

    Prior Authorization

    Prior authorization — None specified; coverage tied to indications

    No explicit prior authorization requirement is stated in this policy; reimbursement is determined by whether the test meets the listed clinical indications and timing requirements.

    Step Therapy

    Testing sequence — Total testosterone first; free/bioavailable for follow-up

    Measure serum total testosterone as the initial test for suspected cases; reserve measurement of serum free or bioavailable testosterone for confirmatory evaluation when total testosterone is low/borderline or when disorders affecting SHBG are suspected.

    Documentation Required

    Ordering and Documentation Requirements

    Billing Rule

    ORDERING REQUIREMENTS — Order per indications; document timing and reason; code claims correctly

    Order tests that are consistent with the policy's reimbursable clinical indications, document the clinical reason and specimen timing, and submit claims using standard, valid coding; claims may be subject to review.

    • Document clinical indication (e.g., symptoms, monitoring therapy, suspected SHBG disorder).
    • Document timing per frequency limits (e.g., two initial total testosterone measurements ≥24 hours apart; follow-up ≥60 days if indicated).
    • Use valid code combinations from standard code sets when submitting claims.

    Not Covered / Exclusions

    The use of saliva for measurement of testosterone is explicitly listed as not covered and is not reimbursable.

    Ordering serum free and/or bioavailable testosterone as the initial or primary assay without first obtaining a serum total testosterone measurement is not covered.

    Measurement of testosterone for the identification of androgen deficiency in women is not covered.

    Measurement of serum dihydrotestosterone for indications that are not specifically listed among the reimbursable situations is not covered.

    Background and Assay Guidance

    Serum total testosterone exhibits considerable biological variability. Collect specimens in the early morning after fasting when possible. Because of assay variability, the policy strongly recommends using an assay certified by the CDC HoSt/Testosterone program; CDC‑certified assays are standardized to within ±6.4% of the CDC reference standard and a certified‑assay list is available on the HoSt website. When measuring total testosterone in females, use technology with sufficient sensitivity to detect the low levels normally present in females.

    Definitions and Key Concepts

    inv-15: Initial male screening — two serum total testosterone measurements at least 24 hours apart; follow-up timing guidance
    Initial male screeningTwo serum total testosterone measurements at least 24 hours apart
    Follow-up guidanceIf initial screening normal but symptoms persist, follow-up testing allowed no sooner than 60 days after initial screening
    Collection timingCollect early morning after fasting (see Note 1)
    inv-16: Monitoring on testosterone therapy — frequency: every 2-3 months first year then annually
    First-year monitoringEvery 2-3 months during the first year after initiation of testosterone therapy or after a change in therapeutic dosage
    After first yearAnnually thereafter

    Revision History

    2026-01-12policy_approvalLatest

    Policy version 1.0 approved; document updated with literature review and references revised; plan effective date set to May 1, 2026.

    2025-01-23literature_review_update

    Document updated with literature review and references revised; reimbursement information unchanged.

    2024-03-15literature_review_update
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyTestosterone
    Policy CodePolicy CPCPLAB009
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewJan 12, 2026
    Next Review Date
    Key ActionOrder serum total testosterone as the initial test for suspected cases and document clinical indication and timing to support reimbursement.
    SourceLink
    On This Page
    Coverage Criteria for Testosterone and Related TestsSpecific Clinical Indications Considered ReimbursableTesting Frequency and Timing RulesProcedure Codes and Coding GuidanceProvider Actions, Documentation, and Billing RequirementsOrdering and Documentation RequirementsNot Covered / ExclusionsBackground and Assay GuidanceDefinitions and Key ConceptsRevision History

    See reimbursement exclusions

    Monitoring therapy — frequency and conditions for men on testosterone replacement or enzyme inhibitors

    Monitoring covered when ALL of the following timing rules are met:

    Testosterone replacement monitoring: For men receiving testosterone replacement therapy: testing every 2–3 months for the first year after initiation of therapy or after a change in therapeutic dosage; annually thereafter.Every 2-3 months for first year; annually thereafter

    Frequency limits for replacement therapy

    Monitoring during enzyme inhibitor therapy: Monitoring of treatment response in men taking enzyme inhibitors for prostate cancer is reimbursable.

    Monitoring indication

    Documentation requirement: Providers must document clinical indication and timing (e.g., initiation date or dosage change) to support monitoring frequency.

    Claims may be subject to review per policy

    Evaluation of androgen excess in symptomatic females — assay sensitivity

    Covered when ALL of the following are true:

    Symptomatic females evaluation: Serum total testosterone measurement for symptomatic females being evaluated for conditions associated with androgen excess (e.g., PCOS, functional hypothalamic amenorrhea).

    Reimbursable only if clinically indicated

    Assay sensitivity requirement: The assay technology must be sensitive enough to detect the low serum total testosterone levels normally found in females.

    See Note 2 — use of appropriately sensitive assays required

    Exclusion: Measurement of serum testosterone for identification of androgen deficiency in women is not reimbursable.

    See exclusions

    Disorders affecting SHBG — measurement of SHBG and free/bioavailable testosterone

    Measurement may be reimbursable when ANY of the following apply:

    Suspected SHBG-altering disorder: For individuals suspected of having a disorder accompanied by increased or decreased SHBG levels, measurement of serum free testosterone using a medically accepted algorithm based on total testosterone, SHBG, and/or albumin, or measurement of bioavailable testosterone may be reimbursable.

    Refer to Note 3 and Note 4 for conditions that alter SHBG

    Confirmed low/borderline total testosterone: For males with total testosterone confirmed as low or borderline low and who have hypogonadism, gynecomastia, or other testicular hypofunction: annual measurements of serum free testosterone, SHBG, and/or albumin may be reimbursable.Annual

    Frequency limit for confirmatory testing

    Ambiguous genitalia or suspected 5-alpha reductase deficiency — serum dihydrotestosterone

    Measurement may be reimbursable when ANY of the following clinical criteria are met:

    Diagnostic indication: For individuals with ambiguous genitalia, hypospadias, or microphallus: measurement of serum dihydrotestosterone for the diagnosis of 5‑alpha reductase deficiency may be reimbursable.

    Diagnostic use only

    Not reimbursable elsewhere: Measurement of serum dihydrotestosterone is not reimbursable for situations not specifically listed as reimbursable.

    See reimbursement exclusions

    DocumentationClinical documentation should support timing and persistent symptoms for follow-up testing
    inv-24: monitoring serum testosterone during replacement therapy — Every 2-3 months then annually
    Initial monitoring frequencyEvery 2-3 months during the first year after initiation of testosterone therapy or after a change in therapeutic dosage
    Long-term monitoringAnnually thereafter
    Also applies toMonitoring treatment response in men taking enzyme inhibitors for prostate cancer (per covered indications)
    inv-25: serum estradiol — Once per lifetime
    FrequencyOnce per lifetime prior to initiating testosterone therapy for males with gynecomastia
    TestSerum estradiol measurement
    PurposeBaseline evaluation before starting testosterone therapy in males with gynecomastia
    inv-26: free testosterone, SHBG, and/or albumin for males with confirmed low/borderline total testosterone and hypogonadism/gynecomastia/testicular hypofunction — Annual
    FrequencyAnnual measurements of serum free testosterone, SHBG, and/or albumin
    IndicationMales with total testosterone confirmed as low or borderline low and who have hypogonadism, gynecomastia, or other testicular hypofunction
    UseTo evaluate free or bioavailable testosterone and account for SHBG-related alterations

    Clinical documentation and timing — Support indication and timing

    Providers must submit accurate documentation that supports the clinical indication for testing and the timing of specimen collection and repeat testing per the policy (e.g., two total testosterone measurements ≥24 hours apart for initial male screening; follow-up testing no sooner than 60 days when initial screening is normal). Claims must use valid code combinations.

    Denial Risk

    Saliva testing excluded — Not reimbursable

    The use of saliva for measurement of testosterone is not reimbursable; claims for saliva-based testosterone testing will be denied.

    Denial Risk

    Primary free/bioavailable testing without prior total — Not reimbursable

    Measurement of serum free and/or bioavailable testosterone as a primary test without a prior serum total testosterone measurement is not reimbursable and may be denied.

    ContextApplies to men receiving testosterone replacement therapy and for therapy monitoring in gender-dysphoric/gender-incongruent persons

    Document updated with literature review and references revised; reimbursement information unchanged.

    2023-11-01content_revision

    Document updated with literature review; added initial screening and follow-up screening language to reimbursement item 1a and added Note 1 (collection timing) and Note 2 (assay sensitivity for females); other reimbursement information revised and references updated.

    2022-11-01policy_creation

    New policy created.